These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 20570058)

  • 1. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
    Cakic V; Potkonyak J; Marshall A
    Drug Alcohol Depend; 2010 Sep; 111(1-2):30-7. PubMed ID: 20570058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism and urinary disposition of N,N-dimethyltryptamine after oral and smoked administration: a comparative study.
    Riba J; McIlhenny EH; Bouso JC; Barker SA
    Drug Test Anal; 2015 May; 7(5):401-6. PubMed ID: 25069786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges.
    McKenna DJ
    Pharmacol Ther; 2004 May; 102(2):111-29. PubMed ID: 15163593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
    Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
    J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis.
    Heekeren K; Neukirch A; Daumann J; Stoll M; Obradovic M; Kovar KA; Geyer MA; Gouzoulis-Mayfrank E
    J Psychopharmacol; 2007 May; 21(3):312-20. PubMed ID: 17591658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids.
    Gable RS
    Addiction; 2007 Jan; 102(1):24-34. PubMed ID: 17207120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament.
    Halpern JH; Sherwood AR; Passie T; Blackwell KC; Ruttenber AJ
    Med Sci Monit; 2008 Aug; 14(8):SR15-22. PubMed ID: 18668010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential tolerance to biological and subjective effects of four closely spaced doses of N,N-dimethyltryptamine in humans.
    Strassman RJ; Qualls CR; Berg LM
    Biol Psychiatry; 1996 May; 39(9):784-95. PubMed ID: 8731519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
    Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
    Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The epidemiology of 5-methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption.
    Davis AK; Barsuglia JP; Lancelotta R; Grant RM; Renn E
    J Psychopharmacol; 2018 Jul; 32(7):779-792. PubMed ID: 29708042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics.
    Riba J; Valle M; Urbano G; Yritia M; Morte A; Barbanoj MJ
    J Pharmacol Exp Ther; 2003 Jul; 306(1):73-83. PubMed ID: 12660312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects.
    Strassman RJ; Qualls CR
    Arch Gen Psychiatry; 1994 Feb; 51(2):85-97. PubMed ID: 8297216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids
    Brito-da-Costa AM; Dias-da-Silva D; Gomes NGM; Dinis-Oliveira RJ; Madureira-Carvalho Á
    Pharmaceuticals (Basel); 2020 Oct; 13(11):. PubMed ID: 33114119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample.
    Winstock AR; Kaar S; Borschmann R
    J Psychopharmacol; 2014 Jan; 28(1):49-54. PubMed ID: 24284475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
    Riba J; McIlhenny EH; Valle M; Bouso JC; Barker SA
    Drug Test Anal; 2012; 4(7-8):610-6. PubMed ID: 22514127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dimethyltryptamine: Endogenous Role and Therapeutic Potential.
    Rodrigues AV; Almeida FJ; Vieira-Coelho MA
    J Psychoactive Drugs; 2019; 51(4):299-310. PubMed ID: 31018803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of addiction severity among ritual users of ayahuasca.
    Fábregas JM; González D; Fondevila S; Cutchet M; Fernández X; Barbosa PC; Alcázar-Córcoles MÁ; Barbanoj MJ; Riba J; Bouso JC
    Drug Alcohol Depend; 2010 Oct; 111(3):257-61. PubMed ID: 20554400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
    Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
    Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members.
    Santos RG; Landeira-Fernandez J; Strassman RJ; Motta V; Cruz AP
    J Ethnopharmacol; 2007 Jul; 112(3):507-13. PubMed ID: 17532158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of ayahuasca administered in two repeated doses.
    Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
    Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.